![Michael Nohaile](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Nohaile
Directeur/Membre du Conseil chez
FULGENT GENETICS, INC.
Fortune : 504 341 $ au 30/06/2026
Profil
Michael Nohaile is Chief Executive Officer at Prellis Biologics, Inc. since 2022 and Independent Director at Fulgent Genetics, Inc. since 2022.
Former roles include Director at Genoptix, Inc., General Manager-Molecular Diagnostics Business at Novartis Corp.
from 2007 to 2012, Partner at McKinsey & Co., Inc. from 2000 to 2007, Senior VP-Strategy, Commercialization & Innovation at Amgen, Inc. from 2012 to 2021, Global Head-Molecular Diagnostics at Novartis AG from 2008 to 2012, and Chief Scientific Officer at Generate Biomedicines, Inc. from 2021 to 2022.
Education includes undergraduate studies at Massachusetts Institute of Technology and a doctorate from the University of California, Berkeley.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
FULGENT GENETICS, INC. 0,08 % | 14/05/2026 | 24 578 ( 0,08 % ) | 504 341 $ | 30/06/2026 |
Postes actifs de Michael Nohaile
| Sociétés | Poste | Début |
|---|---|---|
| FULGENT GENETICS, INC. | Directeur/Membre du Conseil | 01/08/2022 |
Prellis Biologics, Inc.
 Prellis Biologics, Inc. BiotechnologyHealth Technology Develops novel technology to bio print vascularized human tissues | Directeur Général | 11/08/2022 |
Anciens postes connus de Michael Nohaile
| Sociétés | Poste | Fin |
|---|---|---|
| GENERATE BIOMEDICINES, INC. | Directeur Technique/Scientifique/R&D | 01/07/2022 |
| AMGEN INC. | Corporate Officer/Principal | 01/02/2021 |
Novartis Corp.
 Novartis Corp. Pharmaceuticals: MajorHealth Technology Manufactures pharmacitical products | Corporate Officer/Principal | 01/11/2012 |
| NOVARTIS AG | Corporate Officer/Principal | 01/11/2012 |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a management consulting firm | Corporate Officer/Principal | 01/01/2007 |
Formation de Michael Nohaile
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
97
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Genoptix, Inc.
 Genoptix, Inc. Medical/Nursing ServicesHealth Services Provides cancer laboratory testing services | Health Services |
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Manufactures pharmacitical products | Health Technology |
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a management consulting firm | Commercial Services |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fulgent Genetics, Inc.
 Fulgent Genetics, Inc. Medical/Nursing ServicesHealth Services Provides genetic diagnostics services | Health Services |
Prellis Biologics, Inc.
Prellis Biologics, Inc. BiotechnologyHealth Technology Develops novel technology to bio print vascularized human tissues | Health Technology |
Generate Biomedicines, Inc.
 Generate Biomedicines, Inc. BiotechnologyHealth Technology Operates as a clinical-stage generative biology company that provides biotechnology and drug design & development services | Health Technology |
Choisissez Zonebourse 
